Clene to Present at the Emerging Growth Conference

Rhea-AI Summary

Clene (Nasdaq: CLNN) announced that its management will deliver a virtual corporate update at the Emerging Growth Conference on August 19, 2026, at 3:10 p.m. ET. The presentation will be webcast via the Events section of Clene’s website and through a dedicated registration link.

According to Clene, a replay will be available through the conference portal and the Emerging Growth YouTube Channel after the event. Clene is a late clinical-stage biopharmaceutical company developing CNM-Au8, an investigational therapy targeting mitochondrial function for neurodegenerative diseases such as ALS, Parkinson’s disease, and multiple sclerosis.

Market Context

A prior conference presentation announcement preceded a -5.41% 24-hour reaction. That event-specific...

Analysis

A prior conference presentation announcement preceded a -5.41% 24-hour reaction. That event-specific history contextualizes this corporate update; the active, ineffective S-3 resale registration and low short positioning are risks to monitor.

Key Figures

Presentation date: August 19, 2026 Presentation time: 3:10 p.m. ET

2 metrics

Presentation date August 19, 2026 Emerging Growth Conference

Presentation time 3:10 p.m. ET Virtual corporate update

Historical Context

5 past events · Latest: Aug 14 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 14	2Q earnings report	Negative	-1.2%	Quarterly loss, financing activity, and regulatory updates accompanied the results.
Aug 10	Clinical data update	Positive	-2.3%	Biomarker analyses linked NfL responses with improved survival and functional outcomes.
Jul 29	Conference presentation	Neutral	-5.4%	Management scheduled a Canaccord conference presentation and investor meetings.
May 14	1Q earnings report	Positive	+8.5%	FDA feedback supported potential accelerated approval and the company reported first-quarter results.
May 05	Public offering	Negative	-18.7%	Clene priced a registered direct offering of common stock for gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clene's recent news reactions were mixed: positive clinical and conference-related announcements were followed by declines, while financing and earnings reactions varied.

Key Terms

mitochondrial health, amyotrophic lateral sclerosis, mitochondrial function, oxidative stress

4 terms

mitochondrial health medical

"focused on improving mitochondrial health and protecting neuronal function"

Mitochondrial health describes how well the tiny energy-producing parts of cells — often called cellular “batteries” — are functioning, including their ability to make energy, manage waste, and avoid damage. It matters to investors because therapies, diagnostics, or supplements aimed at improving mitochondrial health can affect treatment options for aging, metabolic and neurodegenerative diseases, influencing clinical trial prospects, regulatory paths, and potential market size much like a new engine technology can change demand in an industry.

amyotrophic lateral sclerosis medical

"including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis"

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

mitochondrial function medical

"via a mechanism that targets mitochondrial function and the NAD pathway"

Mitochondrial function describes how well mitochondria — the cell’s tiny power plants — produce energy and keep cells healthy. Investors watch it because many drugs, diagnostics and safety tests target or rely on healthy mitochondria; changes in mitochondrial function can signal a treatment’s effectiveness, side effects, or a new market opportunity in diseases tied to energy failure. Think of it as a company’s engine performance indicator for biological systems.

oxidative stress medical

"while reducing oxidative stress"

Oxidative stress is a biological imbalance where damaging, unstable molecules overwhelm the body’s neutralizing defenses, similar to how rust forms when metal is exposed to oxygen and moisture. Investors should care because oxidative stress is linked to many diseases and aging processes, influencing demand for drugs, diagnostics, supplements, and healthcare spending, and it can affect the commercial value and regulatory outlook of related products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference.

Virtual Presentation Details
Date: August 19, 2026
Time of Presentation: 3:10 p.m. ET
Format: Corporate update

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast here: https://goto.webcasts.com/starthere.jsp?ei=1764701&tp_key=7a35454f76&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.

About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
Media Contact: Caroline Wagner, FTP; CWagner@ftpadvocacy.com; (267) 294-6563 

FAQ

When will Clene (NASDAQ: CLNN) present at the Emerging Growth Conference in August 2026?

Clene will present at the Emerging Growth Conference on August 19, 2026, at 3:10 p.m. ET. According to Clene, the session will be a virtual corporate update delivered via webcast for investors and analysts.

How can investors watch Clene’s CLNN Emerging Growth Conference webcast and replay?

Investors can watch Clene’s webcast through the Events section of the company’s website or via the provided registration link. According to Clene, a replay will be accessible on the conference portal and the Emerging Growth YouTube Channel after the event.

What is the format of Clene’s (CLNN) presentation at the Emerging Growth Conference?

Clene’s presentation will be a virtual corporate update webcast on August 19, 2026, at 3:10 p.m. ET. According to Clene, the event is part of the Emerging Growth Conference’s online video webcast sessions for public growth companies.

What does Clene (NASDAQ: CLNN) do as a late clinical-stage biopharmaceutical company?

Clene is a late clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases by improving mitochondrial health and protecting neuronal function. According to Clene, its lead investigational therapy, CNM-Au8, targets mitochondrial function and the NAD pathway while reducing oxidative stress.

Which neurodegenerative diseases is Clene’s CNM-Au8 being developed to address?

CNM-Au8 is being developed to treat amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. According to Clene, the investigational therapy aims to improve central nervous system cell survival and function by targeting mitochondrial function and reducing oxidative stress.

Where is Clene (CLNN) headquartered and where are its R&D operations located?

Clene is based in Salt Lake City, Utah, with research and development and manufacturing operations in Maryland. According to Clene, these sites support development of its investigational neurodegenerative disease therapy CNM-Au8 and related nanomedicine programs.